BACKGROUND AND PURPOSE: We showed previously robust neuroprotection with the thrombin inhibitor argatroban and now sought additional support for its neuroprotective potential. METHODS: We used behavioral and histological end points; rigorously blinded the study groups; extended the treatment window to 3 hours after ischemia onset; and used 2 separate models. First, 2-hour filament middle cerebral artery occlusion in 64 male Sprague-Dawley rats was followed by learning and memory testing and quantitative histomorphometry. Randomly assigned treatment was 0.45 mg argatroban, saline, or 0.4 U thrombin. Second, we used the quantal bioassay (n=272) after 2-hour middle cerebral artery occlusion to detect the longest time delay after which therapy failed. RESULTS:Argatroban powerfully and significantly reversed learning and memory deficits because of focal ischemia compared with saline or thrombin (P<0.03; ANOVA). Argatroban was significantly (P<0.05; t test with Bonferroni) protective when given immediately or after 1, 2, 3, but not 4 hours delay. CONCLUSIONS: We obtained supportive evidence for argatroban protection of the neurovascular unit using behavioral and histological measurements at realistic therapeutic time windows.
RCT Entities:
BACKGROUND AND PURPOSE: We showed previously robust neuroprotection with the thrombin inhibitor argatroban and now sought additional support for its neuroprotective potential. METHODS: We used behavioral and histological end points; rigorously blinded the study groups; extended the treatment window to 3 hours after ischemia onset; and used 2 separate models. First, 2-hour filament middle cerebral artery occlusion in 64 male Sprague-Dawley rats was followed by learning and memory testing and quantitative histomorphometry. Randomly assigned treatment was 0.45 mg argatroban, saline, or 0.4 U thrombin. Second, we used the quantal bioassay (n=272) after 2-hour middle cerebral artery occlusion to detect the longest time delay after which therapy failed. RESULTS:Argatroban powerfully and significantly reversed learning and memory deficits because of focal ischemia compared with saline or thrombin (P<0.03; ANOVA). Argatroban was significantly (P<0.05; t test with Bonferroni) protective when given immediately or after 1, 2, 3, but not 4 hours delay. CONCLUSIONS: We obtained supportive evidence for argatroban protection of the neurovascular unit using behavioral and histological measurements at realistic therapeutic time windows.
Authors: Victoria E O'Collins; Malcolm R Macleod; Geoffrey A Donnan; Laura L Horky; Bart H van der Worp; David W Howells Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422
Authors: Bo Chen; Beth Friedman; Michael A Whitney; Jessica A Van Winkle; I-Farn Lei; Emilia S Olson; Qun Cheng; Benedict Pereira; Lifu Zhao; Roger Y Tsien; Patrick D Lyden Journal: J Neurosci Date: 2012-05-30 Impact factor: 6.167
Authors: Jessica A Van Winkle; Bo Chen; I-Farn Lei; Benedict Pereira; Padmesh S Rajput; Patrick D Lyden Journal: J Neurosci Methods Date: 2012-12-20 Impact factor: 2.390
Authors: Marc Fisher; Giora Feuerstein; David W Howells; Patricia D Hurn; Thomas A Kent; Sean I Savitz; Eng H Lo Journal: Stroke Date: 2009-02-26 Impact factor: 7.914
Authors: Padmesh S Rajput; Jessica A Lamb; Jose Á Fernández; Jilin Bai; Benedict R Pereira; I-Farn Lei; Jennifer Leung; John H Griffin; Patrick D Lyden Journal: Brain Res Date: 2019-03-14 Impact factor: 3.252
Authors: Andrew D Barreto; Gary A Ford; Loren Shen; Claudia Pedroza; Jon Tyson; Chunyan Cai; Mohammad H Rahbar; James C Grotta Journal: Stroke Date: 2017-05-15 Impact factor: 7.914
Authors: P S Rajput; P D Lyden; B Chen; J A Lamb; B Pereira; A Lamb; L Zhao; I-F Lei; J Bai Journal: Neuroscience Date: 2014-09-28 Impact factor: 3.590
Authors: Padmesh S Rajput; Jessica Lamb; Shweta Kothari; Benedict Pereira; Daniel Soetkamp; Yizhou Wang; Jie Tang; Jennifer E Van Eyk; Eric S Mullins; Patrick D Lyden Journal: Glia Date: 2019-08-27 Impact factor: 7.452